Radioactive therapy targets Hard-to-Treat cancers in new trial
NCT ID NCT05867615
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a radioactive drug called 177Lu-PSMA in 83 people with advanced or metastatic cancers that show up on a PSMA PET scan. The drug is given intravenously every 8 weeks for up to 4 cycles. The main goals are to check safety and see if the treatment can control the disease. It is for patients who have no other effective options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lutetium-177 PSMA (a radioactive drug that targets cancer cells)
- What this could lead to
- If successful, this could provide a new treatment option for patients with advanced cancers that show PSMA on scans, potentially controlling tumor growth.
- What could go wrong
- This is an early phase 2 trial with only 83 participants, so results may not apply to all patients. The radioactive drug can cause side effects like fatigue, low blood counts, or kidney issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED / METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UO Medicina Nucleare, AUSL della Romagna
Cesena, 47521, Italy
-
UO Medicina Nucleare, IRCCS IRST
Meldola, Forlì, 47014, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?